We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
-10.34%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.59B
AUM Growth
+$58.5M
Cap. Flow
+$270M
Cap. Flow %
17.04%
Top 10 Hldgs %
54.43%
Holding
78
New
26
Increased
17
Reduced
7
Closed
12

Top Buys

Rank Stock Value
1
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$50.8M
2
ELAN icon
Elanco Animal Health
ELAN
+$41.9M
3
KVUE icon
Kenvue
KVUE
+$41.7M
4
SNY icon
Sanofi
SNY
+$37.1M
5
MRK icon
Merck
MRK
+$21.7M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$51.1M
2
EXEL icon
Exelixis
EXEL
+$36.2M
3
BSX icon
Boston Scientific
BSX
+$32.9M
4
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$32.9M
5
AZN icon
AstraZeneca
AZN
+$22.9M

Sector Composition

Rank Sector Weight
1 Healthcare 85.69%
2 Consumer Staples 2.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BOLT icon
51
Bolt Biotherapeutics
BOLT
$7.63M
$2.86M 0.18%
137,722
– –
MRNS
52
CALL
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$2.58M 0.16%
320,600
+120,600
+60% +$1M
AGEN
53
CALL
Agenus
AGEN
$255M
$1.81M 0.11%
+80,000
New +$2.27M
IMTXW
54
DELISTED
Immatics N.V. Warrants
IMTXW
$1.13M 0.07%
+318,896
New +$1.13M
SYK icon
55
Stryker
SYK
$129B
$896K 0.06%
+3,279
New +$940K
PDSB icon
56
PDS Biotechnology
PDSB
$38.7M
$720K 0.05%
142,635
– –
SVRA icon
57
Savara
SVRA
$1.11B
$597K 0.04%
157,908
+61,660
+64% +$220K
GRTX
58
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$540K 0.03%
3,083,712
– –
IMA
59
ImageneBio Inc
IMA
$63.2M
$501K 0.03%
+9,643
New +$581K
FUSN
60
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$304K 0.02%
117,099
– –
MIRM icon
61
Mirum Pharmaceuticals
MIRM
$6.96B
$287K 0.02%
9,089
– –
CBAY
62
PUT
DELISTED
Cymabay Therapeutics
CBAY
$165K 0.01%
+11,040
New +$146K
SPRB
63
Spruce Biosciences
SPRB
$116M
$131K 0.01%
774
– –
SYBX
64
DELISTED
Synlogic
SYBX
$108K 0.01%
38,331
– –
ALLK
65
DELISTED
Allakos
ALLK
– –
-62,465
Closed -$272K
BAX icon
66
Baxter International
BAX
$12.1B
– –
-362,200
Closed -$16.5M
BSX icon
67
Boston Scientific
BSX
$67.6B
– –
-608,861
Closed -$32.9M
KYNB
68
CALL
Kyntra Bio
KYNB
$28.5M
– –
-10,000
Closed -$675K
KYNB
69
Kyntra Bio
KYNB
$28.5M
– –
-25,503
Closed -$1.72M
KYNB
70
PUT
Kyntra Bio
KYNB
$28.5M
– –
-26,000
Closed -$1.75M
PTCT icon
71
PTC Therapeutics
PTCT
$6.29B
– –
-260,443
Closed -$10.6M
RVMD icon
72
Revolution Medicines
RVMD
$40B
– –
-520,377
Closed -$13.9M
VIR icon
73
Vir Biotechnology
VIR
$1.48B
– –
-488,117
Closed -$12M
VIR icon
74
PUT
Vir Biotechnology
VIR
$1.48B
– –
-300,000
Closed -$7.36M
VRTX icon
75
Vertex Pharmaceuticals
VRTX
$122B
– –
-145,300
Closed -$51.1M
1 2
3
4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q3 2023 Portfolio in Review

As of Q3 2023, Sofinnova Investments held 78 positions worth $1.59B, up 3.8% from $1.53B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Sofinnova Investments deployed $270M of net new capital in Q3 2023, opening 26 new positions and adding to 17 existing holdings. Its largest new stake was RayzeBio, Inc. Common Stock: 2,419,528 shares worth $53.7M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 98% a quarter earlier, followed by Consumer Staples.

On the sell side, the largest reduction was Exelixis, an estimated $36.2M trimmed.

  • Sofinnova Investments's largest Q3 2023 buy was RayzeBio, Inc. Common Stock: 2,419,528 shares worth $53.7M.
  • Sofinnova Investments added most to Merck in Q3 2023, an estimated $21.7M increase.
  • Sofinnova Investments's biggest Q3 2023 reduction was Exelixis, cutting an estimated $36.2M.
  • Sofinnova Investments fully exited Vertex Pharmaceuticals in Q3 2023, selling an estimated $51.1M.
  • Sofinnova Investments's ten largest holdings make up 54% of its $1.59B portfolio in Q3 2023.
  • Sofinnova Investments opened 26 new positions and closed 12 in Q3 2023.
  • Sofinnova Investments's portfolio value rose 3.8% quarter-over-quarter to $1.59B.

Based on Sofinnova Investments's 13F filing for Q3 2023, filed 14 Nov 2023.